Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Semin Arthritis Rheum. 2022 Jun 28;56:152056. doi: 10.1016/j.semarthrit.2022.152056

Table 1.

Pretreatment demographic and clinical data for the study population.

Pretreatment Non-Responders Responders p-value
Subjects, n 9 11 —
Female sex, n (%) 6 (67%) 8 (73%) 1.00
Current Smoker, n (%) 3 (33%) 1 (9%) 0.28
Age (years) 59 [43,75] 49 [24,64] 0.30
Time from Symptoms to Diagnosis (mo) 7.5 [3.5,16] 9 [3.5,22.5] 1.00
Time from Diagnosis to MTX Initiation (mo) 0 [0,4.5] 0 [0,6] 1.00
SJC (0–28) 4 [3,9] 7 [6,15] 0.32
TJC (0–28) 4 [2,9] 7 [5,18] 0.09
ESR (mm/hr) 19 [14,34] 25 [16,33] 0.42
Patient Global Assessment (0–100mm) 49 [37,61] 44 [34,65] 0.70
DAS28-ESR 4.6 [3.9,5.5] 5.7 [4.7,6.2] 0.11
ΔDAS28-ESR −0.50 [−0.75,0.35] −3.6 [−4.6,−2.7] 0.002

RA patients were characterized as “Responders” and “Non-Responders” based on a reduction in DAS28-ESR of greater than or less than 1.2. respectively. Data is presented as median [IQR] unless otherwise noted. Swollen Joint Count (SJC); Tender Joint Count (TJC); Erythrocyte Sedimentation Rate (ESR); Disease Activity Score (DAS28-ESR); Change in DAS28-ESR (ΔDAS28-ESR).